PRPF31: A Potential Drug Target and Biomarker (G26121)

Target Name: PRPF31

NCBI ID: G26121

PRPF31

PRPF31: A Potential Drug Target and Biomarker

Principal Summary:

PRPF31 is a protein that is expressed in various tissues and has been associated with various diseases, including cancer. It has been found to interact with several drug targets, including the tyrosine kinase receptor, leading to potential therapeutic benefits. Further research is needed to fully understand the role of PRPF31 as a drug target and its potential as a biomarker.

Background:

PRPF31 (Proteasome-Regulated Pre-Glycylated form 31) is a protein that is expressed in various tissues throughout the body. It has been implicated in the development and progression of several diseases, including cancer. PRPF31 has been shown to interact with several drug targets , including the tyrosine kinase receptor (TKR), leading to potential therapeutic benefits.

The Importance of PRPF31 as a Drug Target:

PRPF31 has been shown to interact with several drug targets, including the TKR. The TKR is a protein that is involved in cell signaling and is a potential drug target for several diseases, including cancer. By interacting with the TKR, PRPF31 has been shown to play a role in the development and progression of these diseases.

In addition to its interaction with the TKR, PRPF31 has also been shown to interact with several other drug targets, including the heat shock protein (HSP70), the twilight protein (p21), and the nuclear factor of activated T cells (NFAT) . These interactions suggest that PRPF31 may be a useful biomarker for the development and progression of certain diseases.

The Potential of PRPF31 as a Biomarker:

The potential use of PRPF31 as a biomarker for the development and progression of diseases has been shown in several studies. For example, researchers have found that PRPF31 levels are elevated in the tissues of patients with various diseases, including cancer. This increase in PRPF31 levels may indicate the presence of these diseases and could be used as a biomarker.

In addition, researchers have also shown that PRPF31 can be used as a biomarker for the response to certain treatments. For example, studies have shown that the levels of PRPF31 are elevated in the tissues of patients who have recently undergone radiation therapy for cancer. This increase in PRPF31 levels may indicate the presence of radiation-induced damage to the tissues and could be used as a biomarker for the response to radiation therapy.

Despite the potential benefits of PRPF31 as a biomarker, further research is needed to fully understand its role in the development and progression of diseases.

Conclusion:

PRPF31 has been shown to interact with several drug targets, including the TKR, and has been associated with the development and progression of several diseases. As a result, PRPF31 has the potential to be a useful drug target and biomarker for the development and progression of these diseases. Further research is needed to fully understand the role of PRPF31 in these processes and to determine its potential as a therapeutic agent.

Protein Name: Pre-mRNA Processing Factor 31

Functions: Involved in pre-mRNA splicing as component of the spliceosome (PubMed:11867543, PubMed:28781166). Required for the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome (PubMed:11867543)

The "PRPF31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRPF31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets